Segment Data (Tables)

3 Months Ended

Dec. 26, 2014

Schedule of Segment Reporting Information by Business Segment

Selected information by business segment was as follows:



	Three Months Ended
	December 26, 2014			December 27, 2013
Net sales:
Specialty Brands	$	373.6		$	59.6
Specialty Generics	284.2			249.9
Global Medical Imaging	199.3			218.6
Net sales of operating segments ⁽¹⁾	857.1			528.1
Other ⁽²⁾	9.2			12.1
Net sales	$	866.3		$	540.2
Operating income:
Specialty Brands	$	148.2		$	(8.2	)
Specialty Generics	140.5			121.2
Global Medical Imaging	17.3			4.4
Segment operating income	306.0			117.4
Unallocated amounts:
Corporate and allocated expenses ⁽³⁾	(45.8		)	(25.2		)
Intangible asset amortization	(125.5		)	(8.8		)
Restructuring and related charges, net ⁽⁴⁾	(7.3		)	(8.1		)
Separation costs	—			(2.2		)
Operating income	$	127.4		$	73.1


(1)	Amounts represent sales to external customers.


(2)	Represents products that were sold to the Company's former parent company, which is discussed in Note 14.


(3)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(4)	Includes restructuring-related accelerated depreciation of $0.1 million for both the three months ended December 26, 2014 and December 27, 2013.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's segments are as follows:



	Three Months Ended
	December 26, 2014		December 27, 2013
Acthar	$	266.4	$	—
Ofirmev	71.4		—
EXALGO®	12.1		36.2
Other	23.7		23.4
Specialty Brands	$	373.6	$	59.6

Oxycodone (API) and oxycodone-containing tablets	$	47.0	$	11.6
Hydrocodone (API) and hydrocodone-containing tablets	34.0		30.1
Methylphenidate ER	48.6		56.3
Other controlled substances	111.9		120.2
Other	42.7		31.7
Specialty Generics	$	284.2	$	249.9

Optiray™	$	61.5	$	72.1
Other	35.9		39.5
Contrast Media and Delivery Systems	97.4		111.6
Nuclear Imaging	101.9		107.0
Global Medical Imaging	$	199.3	$	218.6

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details